Added to YB: 2026-04-22
Pitch date: 2026-04-20
CABA [neutral]
Cabaletta Bio, Inc.
+7.18%
current return
Author Info
No bio for this author
Company Info
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Market Cap
$585.3M
Pitch Price
$3.27
Price Target
17.00 (+375%)
Dividend
N/A
EV/EBITDA
-2.88
P/E
-1.71
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Monthly Core Conviction #1: The Full M&A Book - Cabaletta Bio, Inc.
CABA (update): rese-cel CAR-T for autoimmune; myositis BLA targeted 2027, SLE/LN pivotals aligned w/ FDA (~25 pts each). $133.6M cash + $30M Q1 raise = runway to Q4 2026. Cellares automated mfg data 1H-2H26. Analyst PT avg $14.50-$17 (high $30), 300-400%+ upside from $3.44. AAN RESET-MG data Apr 20. M&A window 2027-28 on BLA & durability.
Read full article (1 min)